Skip to content

REFERENCE FILE

Bremelanotide

Examine the reference details alongside the questions and dated sources.

Reference details

Status as of

Regulatory category
Approved product
Evidence category
Randomized evidence
Mechanism
Melanocortin-receptor agonist.
Evidence
Randomized trials.
Limitations
Exclude medical, relationship and drug causes; not performance enhancement.
Safety
Uncontrolled hypertension or known cardiovascular disease: contraindicated.
Formulation and route
Subcutaneous injection.
Approval scope
Vyleesi: eligible premenopausal women with distressing acquired generalized low-desire disorder.

READING NOTES

Questions for a closer look

For a bremelanotide estimate, write a boundary statement naming the circumstances to which your intended interpretation refers. Check that statement against the source's population, measurement conditions and period of observation. Change one circumstance in an explicitly hypothetical application and ask which supporting connection must now be established. Repeat with a different circumstance, keeping the questions separate. Do not assign an invented correction to the estimate when a connection is unresolved. The useful product is a set of conditional statements: the interpretation extends to the new setting only if the specified connections can be justified with relevant evidence.

Questions to investigate

  1. Which circumstances define the application I want the estimate to support?
  2. What connection needs checking when I change one circumstance hypothetically?
  3. What evidence would justify that extension without inventing a numerical correction?

Sources for this file

  1. VYLEESINLM · Checked
  2. Kingsberg trialsPubMed · Checked

MED CONSUMER WATCH · RESEARCH

Read the evidence behind the question.

Browse reference files or follow a study analysis from its question to its limitations.